截至公告披露日，药易购已全额收到4400万元执行款。经公司初步测算，迟延履行债务利息约35.74万 元，目前法院正进一步核对，义务人暂未支付该部分款项，公司将持续跟进后续进展。 此外，公告提及，公司及控股子公司近一年尚有54起未披露的小额诉讼、仲裁事项，涉诉金额合计 2120.81万元，主要为合同纠纷。药易购表示，本次收到的4400万元将按会计准则进行会计处理，最终 对公司本期或期后利润的影响，以审计机构年度审计结果为准。 近日，药易购（300937）发布公告披露了公司与杨亚、曹继军及享健药易购健康科技有限公司的合同纠 纷诉讼，在终审胜诉后已收到4400万元核心执行款项，迟延履行债务利息仍在核对中。 公告显示，该纠纷始于2022年11月，原告杨亚、曹继军就合作协议相关事宜将药易购诉至广州市黄埔区 人民法院。2024年8月，一审法院判决解除相关协议，判令对方共同向药易购偿还借款4400万元；双方 均不服判决提起上诉，2025年10月广州市中级人民法院终审驳回上诉、维持原判，二审案件受理费由对 方承担主要部分。 ...

格隆汇12月25日丨鹭燕医药(002788.SZ)在互动平台表示，公司将通过建立完善的分销网络、全面的终 端客户覆盖体系和批零一体化的经营模式，为各级医疗机构和终端消费者提供医药产品保障服务。 ...

Group 1 - The core point of the article is that Ruikang Pharmaceutical announced a board meeting to discuss the proposal to change the accounting firm and provided details on its revenue composition for the first half of 2025 [1] - Ruikang Pharmaceutical's revenue for the first half of 2025 is primarily derived from drug and medical device sales, which account for 98.42% of total revenue, while mobile healthcare contributes 0.67%, other sources 0.6%, and leasing 0.31% [1] - As of the report, Ruikang Pharmaceutical has a market capitalization of 5.3 billion yuan [2]

Group 1 - The chairman of Shandong Pharmaceutical Glass Co., Ltd., He Yonggang, has resigned, marking a significant personnel change shortly after the company was indirectly controlled by China National Pharmaceutical Group (Sinopharm) [1][19] - He Yonggang, aged 61, has had a long career with Shandong Pharmaceutical Glass, holding various key positions, and his resignation is attributed to age despite his term being set until May 2028 [2][20] - Zhang Jun, the current general manager, has been appointed to take over the chairman's responsibilities, bringing extensive production management and R&D experience to the role [2][20] Group 2 - Shandong Pharmaceutical Glass, established in 1970 and listed in 2002, specializes in the production of pharmaceutical glass packaging, covering a complete pharmaceutical packaging industry chain [4][22] - In June, Sinopharm and its Hong Kong subsidiary invested 2.449 billion yuan in Shandong Pharmaceutical Glass, acquiring a 51% stake in its controlling shareholder, thus indirectly controlling 19.5% of the company [4][22] - The company has achieved a nearly 90% market share in the domestic borosilicate molded bottle sector, which has been historically dominated by international giants [5][22] Group 3 - In 2024, Shandong Pharmaceutical Glass reported revenues of 5.125 billion yuan, a year-on-year increase of 287 million yuan, and a net profit of 904 million yuan, up 21.86% [5][22] - However, in the first three quarters of 2025, the company experienced a revenue decline of 11.1% to 3.4 billion yuan and a net profit drop of 24.7% to 543 million yuan, attributed to product homogenization and weak downstream demand [5][23] - The overall pharmaceutical distribution industry in China is experiencing a slowdown, prompting a trend towards consolidation among major players [14][30] Group 4 - Sinopharm is undergoing significant personnel changes across its pharmaceutical distribution companies, reflecting potential strategic shifts within the organization [6][13] - Recent leadership changes include the resignation of several key executives, indicating a response to the challenges faced by the company, including declining revenue growth [6][29] - Sinopharm is focusing on expanding its market presence by enhancing core customer relationships and increasing the share of high-value products in its overall revenue [31]

Group 1 - The core viewpoint of the news is that Dajia Weikang's stock performance and financial metrics indicate a mixed outlook, with a decline in net profit despite a slight increase in revenue [2][3] - On December 23, Dajia Weikang's stock fell by 1.30%, with a trading volume of 161 million yuan. The financing buy-in amount was 17.99 million yuan, while the net financing buy-in was 7.12 million yuan [1] - As of December 23, the total balance of margin trading for Dajia Weikang was 77.92 million yuan, with the financing balance accounting for 2.92% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of December 10, the number of shareholders for Dajia Weikang was 16,000, a decrease of 2.42%, while the average circulating shares per person increased by 2.48% to 8,620 shares [2] - For the period from January to September 2025, Dajia Weikang achieved an operating income of 4.13 billion yuan, a year-on-year increase of 3.69%, but the net profit attributable to shareholders decreased by 86.02% to 5.10 million yuan [2] - Dajia Weikang has distributed a total of 42.59 million yuan in dividends since its A-share listing, with 35.57 million yuan distributed over the past three years [3]

（编辑 王雪儿） 证券日报网讯 12月23日，老百姓发布公告称，截至本公告披露日，公司对外担保总额9.8亿元，占公司 最近一期经审计净资产的比例为13.69%，公司对外担保余额为4.4亿元（含本次担保），上述对外担保 总额全部为公司对合并报表范围内子公司提供的担保，公司不存在对控股股东和实际控制人及其关联人 提供担保情况，也不存在逾期对外担保情况。 ...

资金流向方面，今日该股主力资金净流出3696.38万元，其中，特大单净流入1813.25万元，大单资金净 流出5509.64万元。近5日主力资金净流出1.68亿元。（数据宝） 鹭燕医药今日涨停，全天换手率25.91%，成交额17.24亿元，振幅16.21%。龙虎榜数据显示，机构净卖 出6.35万元，营业部席位合计净卖出4871.21万元。 深交所公开信息显示，当日该股因日振幅值达16.21%上榜，机构专用席位净卖出6.35万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交3.24亿元，其中，买入成交额为1.38亿 元，卖出成交额为1.86亿元，合计净卖出4877.56万元。 具体来看，今日上榜的营业部中，共有5家机构专用席位现身，即买一、买二、买三、买四、卖二、卖 三、卖五，合计买入金额1.13亿元，卖出金额1.13亿元，合计净卖出6.35万元。 鹭燕医药12月23日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 机构专用 | 3152.26 | 2064.37 | | 买二 | 机构 ...

卖一 深股通专用 2416.93 4423.93 卖二 机构专用 1410.50 3028.26 卖三 机构专用 2730.38 2908.43 卖四 机构专用 2018.97 2826.78 卖五 机构专用 2933.34 2061.64 近半年该股累计上榜龙虎榜7次，上榜次日股价平均涨2.47%，上榜后5日平均跌0.72%。 资金流向方面，今日该股主力资金净流出329.21万元，其中，特大单净流出3833.88万元，大单资金净流 入3504.67万元。近5日主力资金净流出223.02万元。 融资融券数据显示，该股最新（12月22日）两融余额为1.90亿元，其中，融资余额为1.89亿元，融券余 额为41.88万元。近5日融资余额合计增加7246.73万元，增幅为62.13%，融券余额合计增加41.73万元， 增幅27932.13%。（数据宝） 华人健康12月23日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 机构专用 | 2933.34 | 2061.64 | | 买二 | 机构专用 | 273 ...

南财智讯12月23日电，鹭燕医药公告，公司股票交易价格连续三个交易日内（2025年12月19日、2025年 12月22日、2025年12月23日）收盘价格涨幅偏离值累计超过20%，根据深圳证券交易所的有关规定，属 于股票交易异常波动的情况。针对上述情况，公司进行了核查并确认：前期披露的信息不存在需要更 正、补充之处；近期公司经营情况正常，内外部经营环境未发生重大变化；未发现近期公共传媒报道了 可能或已经对本公司股票交易价格产生较大影响的未公开重大信息；公司、控股股东和实际控制人不存 在关于本公司的应披露而未披露的重大事项，或处于筹划阶段的重大事项；股票异常波动期间，控股股 东、实际控制人不存在买卖公司股票的情形。公司董事会确认，目前没有任何应予以披露而未披露的事 项，也未获悉任何对本公司股票交易价格产生较大影响的信息。 ...

每经AI快讯，12月23日，鹭燕医药（002788）(002788.SZ)公告称，公司股票交易价格连续三个交易日 内收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动情况。经核实，公司前期披露的信息无需 要更正、补充之处，近期经营正常，内外部经营环境未发生重大变化，未发现公共传媒报道可能或已经 对本公司股票交易价格产生较大影响的未公开重大信息，公司、控股股东和实际控制人不存在关于本公 司的应披露而未披露的重大事项，或处于筹划阶段的重大事项。股票异常波动期间，控股股东、实际控 制人不存在买卖公司股票的情形。 ...